The proportion of tumor-infiltrating CD45+ immune cells was elevated in response to the combination group (Figure S1A) compared to the single-agent treatment groups (anti-CD47 Ab and anti-CTLA4 Ab alone). The gene discussed is CD47; the disease is neoplasm.